RxDoctor Payments Data

Reazyn Demoss

Family · Johnson City, TNNPI 1205437647

Payments from drug & device makers

$5,712in general payments, 2019–2025

Across 349 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$806
  • GSK$485
  • Lilly USA, LLC$352
  • Novo Nordisk$308
  • Boehringer Ingelheim$258
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$5,698100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,712 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$27,123
Medicare patients
73
Services billed
820

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$56,704
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$49,410
JardianceEmpagliflozin25$42,566
MounjaroTirzepatide29$32,878
RexultiBrexpiprazole13$21,128
FarxigaDapagliflozin Propanediol13$17,753
XareltoRivaroxaban14$11,580
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$10,644
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,977
Omeprazole91$2,312
Albuterol Sulfate HfaAlbuterol Sulfate126$2,193
Gabapentin95$1,858
Buspirone Hcl75$1,843
Fluticasone Propionate74$1,541
SynthroidLevothyroxine Sodium15$1,218

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$485$60,05483 claims
Novo NordiskOzempic$308$56,70452 claims
Boehringer IngelheimJardiance$258$42,56625 claims
Lilly USA, LLCMounjaro$352$32,87829 claims
AstraZenecaFarxiga, Breztri Aerosphere$806$25,73025 claims
Otsuka America Pharmaceutical, Inc.Rexulti$151$21,12813 claims
AbbVieSynthroid$1,110$1,21815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.

Other family in Johnson City

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →